全文获取类型
收费全文 | 262510篇 |
免费 | 15379篇 |
国内免费 | 709篇 |
专业分类
耳鼻咽喉 | 4040篇 |
儿科学 | 9192篇 |
妇产科学 | 5810篇 |
基础医学 | 34788篇 |
口腔科学 | 10601篇 |
临床医学 | 19837篇 |
内科学 | 58670篇 |
皮肤病学 | 7248篇 |
神经病学 | 21828篇 |
特种医学 | 7792篇 |
外国民族医学 | 27篇 |
外科学 | 33832篇 |
综合类 | 1927篇 |
现状与发展 | 1篇 |
一般理论 | 92篇 |
预防医学 | 25382篇 |
眼科学 | 5367篇 |
药学 | 16778篇 |
中国医学 | 1206篇 |
肿瘤学 | 14180篇 |
出版年
2023年 | 1448篇 |
2022年 | 1190篇 |
2021年 | 6241篇 |
2020年 | 3767篇 |
2019年 | 5902篇 |
2018年 | 8127篇 |
2017年 | 5682篇 |
2016年 | 5476篇 |
2015年 | 6232篇 |
2014年 | 8568篇 |
2013年 | 11414篇 |
2012年 | 17436篇 |
2011年 | 18552篇 |
2010年 | 9547篇 |
2009年 | 8189篇 |
2008年 | 14314篇 |
2007年 | 15263篇 |
2006年 | 14350篇 |
2005年 | 14748篇 |
2004年 | 13874篇 |
2003年 | 12689篇 |
2002年 | 10472篇 |
2001年 | 7074篇 |
2000年 | 7304篇 |
1999年 | 6099篇 |
1998年 | 2169篇 |
1997年 | 1818篇 |
1996年 | 1521篇 |
1995年 | 1456篇 |
1994年 | 1394篇 |
1993年 | 1236篇 |
1992年 | 3201篇 |
1991年 | 3028篇 |
1990年 | 2770篇 |
1989年 | 2681篇 |
1988年 | 2457篇 |
1987年 | 2254篇 |
1986年 | 2125篇 |
1985年 | 1998篇 |
1984年 | 1443篇 |
1983年 | 1184篇 |
1982年 | 732篇 |
1981年 | 668篇 |
1980年 | 622篇 |
1979年 | 1106篇 |
1978年 | 744篇 |
1977年 | 564篇 |
1975年 | 618篇 |
1974年 | 666篇 |
1973年 | 644篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
1.
2.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
3.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
4.
5.
María C. Lanuza-López Sandra G. Martínez-Garza Jesús F. Solórzano-Vázquez Daniela Paz-Cervantes Claudia González-Ortega Israel Maldonado-Rosas 《Gynecological endocrinology》2020,36(9):829-834
AbstractOocyte maturation defect is a challenging situation in the management of infertility, the etiology may be related to endocrine causes, protocols used in ovarian stimulation, oocyte intrinsic defects or procedures in embryology laboratory. We report three Mexican females in treatment for primary infertility with non-mature oocytes after ovary stimulation and oocyte capture in whom a genetic diagnosis of TUBB8-oocyte maturation defect was revealed by exome sequencing. Two couples achieved pregnancies though oocyte donation after establishing the genetic etiology. Our results expand the role of TUBB8-disorders in patients of non-Asian ethnicity. Oocyte maturation defects of monogenic origin are a growing group of disorders that endocrinologists and reproductive medicine specialists should be aware in order to provide referral to genetics for establish a correct and opportune diagnosis. 相似文献
6.
Esin Benli Küçük Ercan Kaydok Kürsad Ramazan Zor Gamze Yıldırım Biçer 《Topics in stroke rehabilitation》2020,27(8):630-635
ABSTRACT Objective: Dry eye is reported to be associated with several neurological diseases. The aim of this study is to evaluate the patients with hemiplegia after stroke for dry eye and compare their results with a control group. Materials and methods: Forty-five patients with hemiplegia and 45 individuals as the control group were included in the study. Tear function tests (Schirmer and tear breakup time) and a dry eye questionnaire for dry eye symptoms (ocular surface disease index) were performed and the results of the two groups were compared. Results: Schirmer test results were significantly lower in the post-stroke hemiplegia group compared to the control group (11.3 ± 8.2 mm and 20.6 ± 11.6 mm, respectively, p < .001). Tear breakup time results were significantly lower in the post-stroke hemiplegia group compared to the control group (7.9 ± 3.1 s and 12.1 ± 4.3 s, respectively, p < .001). Ocular surface disease index scores were not significantly different between hemiplegia and control groups (21.6 ± 20.0 and 19.8 ± 13.9, respectively, p = .635). Schirmer scores lower than 10 mm (60% and 30%, p < .001) and tear breakup time results lower than 10 s (65.6% and 28.9%, p < .001) were also higher in the hemiplegia group compared to control group. Conclusion: We found lower Schirmer test and tear breakup time results and similar OSDI scores in hemiplegia patients compared to controls. Hemiplegia patients may have dry eye without typical symptoms. This should be taken into consideration in the follow-up and rehabilitation of post-stroke hemiplegia patients. 相似文献
7.
María del Carmen Azorín Samper Marta Hernandorena Gonzlez Alberto Ibez Arias Sandra Díaz Sierra Marta Bertolo Domínguez Flix Checa Ayet 《The breast journal》2020,26(2):252-254
Breast pseudoaneurysms after a core needle biopsy are a rare complication with a low incidence. However, it is important to be aware of the possibility of complications that require treatment. 相似文献
8.
9.
10.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献